Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aurinia Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
AUPH
Nasdaq
2836
www.auriniapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aurinia Pharmaceuticals Inc.
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
- Jul 22nd, 2026 5:40 am
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
- Jul 6th, 2026 6:00 am
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
- Jul 2nd, 2026 10:00 am
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
- Jun 29th, 2026 2:07 pm
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
- Jun 26th, 2026 2:59 am
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
- Jun 25th, 2026 6:40 am
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
- Jun 23rd, 2026 5:08 am
Aurinia Pharmaceuticals and Four More Stocks See Activist Action
- Jun 12th, 2026 4:47 pm
A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation
- Jun 11th, 2026 8:11 am
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
- Jun 7th, 2026 6:17 am
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
- Jun 4th, 2026 5:00 am
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
- Jun 2nd, 2026 10:43 pm
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
- May 19th, 2026 6:30 am
We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability
- May 15th, 2026 4:38 am
Aurinia Pharmaceuticals Inc. Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next
- May 9th, 2026 7:23 am
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
- May 7th, 2026 9:15 am
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?
- Apr 23rd, 2026 6:41 am
United rises on IPF results; Biogen scores positive lupus data and an approval
- Mar 30th, 2026 9:00 am
Does Aurinia’s Tang‑Led Leadership Overhaul Reshape the Bull Case for Aurinia Pharmaceuticals (AUPH)?
- Mar 29th, 2026 12:03 am
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up
- Mar 23rd, 2026 2:05 pm
Scroll